Efektivitas Penggunaan Obat Antituberkulosis (Oat) Lini Kedua pada Pasien Multidrug Resistant Tuberculosis (Mdr-Tb) di Indonesia

Novaryanti Dwi Putri Septyani, Fetri Lestari, Suwendar Suwendar

Abstract


Abstract. Pulmonary tuberculosis (TB) is still a major health problem in the world, especially in Indonesia. Tuberculosis is caused by the bacterium Mycobacterium tuberculosis. MDR-TB therapy uses at least four antituberculosis drugs (OAT) with the isolate Mycobacterium tuberculosis which is still sensitive including second-line injection OAT. The standard rules of MDR-TB in Indonesia are Km - Lfx - Eto - Cs - Z(E) / Lfx - Eto - Cs - Z - (E). The use of second-line OAT causes mild to severe side effects. So the determination of the regimen for MDR-TB therapy needs consideration in accordance with the physical condition of the patient. This study aims to determine the effectiveness of the use of second-line antituberculosis drugs and side effects that occur in MDR-TB patients in Indonesia. This research was conducted by the literature study method. The data sources used in this study are mostly from various research journals that have been published nationally and internationally. A total of 6 national journals and 3 international journals were used as analysis material. The results of the study mentioned that MDR-TB treatment regimens that comply with the standard rules in Indonesia are still effectively used for MDR-TB patients in Indonesia. During the treatment period the side effects that occur in most patients are digestive disorders, and these side effects can be overcome by adding drugs that are relevant to the side effects and the patien’s condition.

Keywords: Side effects of MDR-TB treatment, MDR-TB, Second Line Antituberculosis drugs.

Abstrak. Tuberkulosis (TB) paru masih menjadi masalah kesehatan utama di dunia terutama di Indonesia. Penyakit Tuberkulosis ini disebabkan oleh bakteri Mycobacterium tuberculosis. Terapi MDR-TB menggunakan setidaknya empat obat antituberkulosis (OAT) dengan isolat Mycobacterium tuberculosis (MTb) yang masih sensitif termasuk OAT injeksi lini kedua. Aturan baku MDR-TB di Indonesia adalah Km –Lfx –Eto –Cs –Z (E) / Lfx – Eto – Cs – Z - (E). Penggunaan OAT lini kedua tersebut menimbulkan efek samping ringan hingga berat. Sehingga penentuan regimen untuk terapi MDR-TB perlu pertimbangan sesuai dengan kondisi fisik pasien. Penelitian ini bertujuan untuk mengetahui efektivitas penggunaan OAT lini kedua dan efek samping yang terjadi pada pasien MDR-TB di Indonesia. Penelitian ini dilakukan dengan metode studi literatur. Sumber data yang digunakan pada penelitian ini sebagian besar dari berbagai jurnal penelitian yang telah dipublikasikan secara nasional dan internasional. Sebanyak 6 jurnal nasional dan 3 jurnal internasional digunakan sebagai bahan analisis. Hasil penelitian menyebutkan bahwa rejimen pengobatan MDR-TB yang sesuai dengan aturan baku di Indonesia masih efektif digunakan untuk pasien MDR-TB di Indonesia. Selama masa pengobatan efek samping yang terjadi pada kebanyakan pasien yaitu gangguan pencernaan. Efek samping ini dapat diatasi dengan penambahan obat yang relevan dengan efek samping serta kondisi pasien.

Kata Kunci: Efek samping pengobatan MDR-TB, MDR-TB, OAT Lini Kedua.


Keywords


Efek samping pengobatan MDR-TB, MDR-TB, OAT Lini Kedua.

Full Text:

PDF

References


Aini, Qurratul, dkk. (2015). Gambaran Efek samping obat anti tuberculosis (OAT) Lini Kedua pada pasien Tuberculosis-Multidrug resistance (TB-MDR) di Poliklinik TB-MDR RSUD Arifin Achmad Provinsi Riau. JOM FK Vol. 1 No. 2 Februari 2015

Anderson LF, Watson JP, Tamne S, Cohen T, Mitnick T, Drobniewski F, Abu-bakar I (2013). Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. European Surveillance, 18(40): 1-10

Andreas H. Diacon, et al. (2014). Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. The New England Journal of Medicine; 371:723-32. DOI: 10.1056/NEJMoa1313865

Curry International Tuberculosis Center. (2012). Tuberculosis Drug Information Guide, 2nd Edition. CITC: Departement of Public Health California

Elisabeth, dkk. (2017). Factors Affecting the Success of Multi Drug Resistance (MDR TB) Tuberculosis Treatment in Residential Surakarta. (Elisabeth, 2017). Jurnal of Epidemiology and Public Health (2017), 2(1): 45-57

Field, Stephen K. (2015). Bedaquilin for the treatment of multidrug-resistant tuberculosis. Ther Adv Chronic Dis Vol. 6(4) 170-184

Kementrian Kesehatan RI Pusat Data dan Informasi. (2018). Tuberkulosis. INFODATIN: Jakarta.

Kementrian Kesehatan RI. (2013). Situasi tbc di Indonesia. Available at (https://tbindonesia.or.id/informasi/tentang-tbc/situasi-tbc-di-indonesia-2/)

Munir, Sri Melati, dkk. (2010). Pengamatan Pasien Tuberkulosis Paru dengan Multidrug Resistant (TB-MDR) di Poliklinik Paru RSUP Persahabatan. J.Respir Indo Vol. 30, No. 2 April 2010

Ni Kadek, dkk. (2016). Hubungan Lama Penggunaan Obat Anti Tuberkulosis dengan Efek Samping pada Pasien TB MDR Rawat Jalan di RSUP Sanglah Denpasar. Arc. Com. Health Vol. 3 No. 2 : 39-48

Nofizar D, Nawas A, Burhan E. (2010). Indentifikasi Faktor Risiko Tuberkulosis Multidrug Resistant (TB-MDR). Maj Kedokteran Indonesia.

Peraturan Menteri Kesehatan RI Nomor 13 Tahun 2013. (2013). Pedoman Manajemen Terpadu Pengendalian Tuberkulosis Resistan Obat. Menteri Kesehatan RI: Jakarta

Peraturan Menteri Kesehatan RI Nomor 67 Tahun 2016. (2016). Penanggulangan Tuberkulosis. Menteri Kesehatan RI: Jakarta

Public Health Agency of Canada. (2010). Tuberculosis (TB) and Tobacco Smoking. Canada: Government of Canada. Available from: http://www.phacaspc.gc.ca/tbpc-latb/fa-fi/tbtobaccotabag-eng,php.

Reviono, Kusmanto, dkk. (2014). Multidrug Resistant Tuberculosis (MDR-TB): Tinjauan Epidemiologi dan Faktor Risiko Efek Samping Obat Anti Tuberkulosis. MKB, Volume 46, No. 4, Desember 2014

Syahrezki, (2015). Faktor Risiko Multidrug Resistant Tuberculosis (MDR-TB). Junral Kesehatan Masyarakat 8(1) (201) 60-66

Vivin, dkk. (2015). Profil Pasien Tuberculosis Multidrug Resistance (TB-MDR) di Poliklinik TB-MDR RSUD Arifin Achmad Provinsi Riau Periode April 2013-Juni 2014. JOM FK Volume 1 No.2 Oktober 2015

World Health Organization. (2014). Tuberculosis Coalition for Technical Assistance. International Standards for Tuberculosis Care (ISTC). The Hague : Tuberculosis Coalition for Technical Assistance

World Health Organization. (2014). WHO guidelines for the programmatic management of drug-resistant tuberculosis. The End TB Strategy: Geneva, Switzerland

World Health Organization. (2018). The top 10 causes of death. Available at https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death




DOI: http://dx.doi.org/10.29313/.v6i2.23506

Flag Counter    Â